Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.
A Randomized, Unicenter, Parallel Study of the Effect of Dapagliflozin on Central Blood Pressure Reduction Compared to Glimepiride in Adult Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control.
Sponsor: IInstituto Gallego de Medicina Vascular
Listed as NCT02919059, this PHASE4 trial focuses on Diabetes Mellitus, Type 2 and remains ongoing. Sponsored by IInstituto Gallego de Medicina Vascular, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Sep 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Sep 2019 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- IInstituto Gallego de Medicina Vascular
For direct contact, visit the study record on ClinicalTrials.gov .